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Hematopoietic stem cell transplantation is used to treat patients with a variety of hematologic 
malignancies. The use of umbilical cord blood transplant (UCBT) has increased as a source for stem 
cells due to availability and less stringent matching requirements for donors and recipients. 
However, there is a higher risk of non-relapse mortality for UCBT compared to other sources of 
hematopoietic stem cells due to delayed recovery of the immune system relative to other transplant 
methods. Cytomegalovirus (CMV) infects 50 to 80% of adults in the United States, and like other 
herpesviruses persists as a life-long latent infection controlled by T cells in healthy individuals. 
Around 10-fold fewer T cells are transferred with UCBT compared to when peripheral blood stem 
cells are used, and these T-cells are naïve with no prior exposure to antigens. Without T cell 
protection in transplant patients, CMV can reactivate and result in mild to life-threatening multi-organ 
disease. Antiviral drug therapy is required for patients to prevent and treat CMV reactivation while 
the immune system recovers. 
Previous research reported that CMV-specific CD8+ T cells were only reliably detected 100 days 
after transplant, after the transplanted T cells had time to mature in the thymus. Drs. Suzanne 
McGoldrick, Colleen Delaney, Stan Riddell and colleagues in the Clinical Research Division used a 
more sensitive assay to assess the reconstitution of T cell immunity to CMV infection after UCBT. 
Using this method, the researchers were able to detect low frequency T cell responses, and 
characterize the stability of responses over time in patients. 
T cells were isolated from 15 CMV seropositive and four seronegative transplant patients at various 
days post transplant and incubated with patient-matched CMV-infected fibroblasts. Infected cells 
display viral antigens on their surface through major histocompatibility (MHC) receptors, which are 
recognized by T cell receptors. CMV can evade host detection by downregulating the expression of 
MHC receptors. For each UCBT patient, fibroblast cell lines were generated and infected with the 
RV798 strain of CMV, which lacks the genes that down-regulate the MHC receptor. CD8+ T cells 
that recognize CMV antigens proliferate, and express and secrete IFNγ to kill infected cells. 
Activated CMV-specific CD8+ T cells were detected by intracellular staining of IFNγ (see figure). 
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CMV-specific CD8+ T cells were detected in 11 of 15 of the CMV seropositive patients between days 
42 and 56, and in two more patients by day 80. While CMV-specific T cells were primed early, 
absolute numbers of T cells were low in patients and failed to control infection; 13 of the 15 CMV 
seropositive patients had virus reactivation and needed antiviral therapy. These early T cells were 
capable of recognizing multiple CMV antigens, so the failure to control infection was probably not 
due to limited antigen detection. 
The researchers then began to address why the CMV-specific CD8+ T cell population size remained 
low during the first several months after UCBT. Patient derived T cells proliferated and remained 
viable in vitro when exposed to CMV infected cells, suggesting that the cells were not inherently 
defective in cell growth or survival. Using another sensitive assay, the researchers found that CMV-
specific CD4+ T cells were also present early, but the population was also small in patients. CD4+ T 
cells regulate the function of CD8+ T cells, and can contribute to low CD8+ T cell numbers in 
patients. Alternatively, the use of immunosuppressive drugs or other environmental factors in 
patients could block T cell expansion. Preliminary studies showed fewer CMV-specific CD8+ T cells 
were recovered from fibroblast co-culture in the presence of immunosuppressive drugs. Further 
supporting this mechanism, viral control coincided with increased T cell numbers and 
immunosuppressive drug reduction in patients. 
According to Dr. McGoldrick, "Our research demonstrates that T cells developing after cord blood 
transplant are capable of recognizing cytomegalovirus, but are unable to accumulate to sufficient 
numbers to control the virus. This finding suggests that immunotherapy with virus-specific T cells 
expanded from the patients blood could be used to treat this complication." This could decrease the 
need for long-term antiviral drugs in transplant patients. 
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A delay in immune reconstitution after cord blood transplant for 
leukemia can lead to patients developing potentially life-
threatening CMV infections. McGoldrick et al. used a sensitive 
assay to detect CMV-specific CD8+ T cells in patients after 
transplant. Patient fibroblasts were isolated and infected with 
CMV. After 48 hours, CD8+ T cells from patients were isolated 
and incubated with the infected fibroblasts. CMV-specific T cells 
will proliferate in response to antigen, and can be selected by 
expression of IFNγ. CMV-specific T cells are present and 
functional after transplant, but fail to expand in sufficient 
numbers to control CMV infection. 
 
